Articles published in Journal of Diabetes & Metabolism have been cited by esteemed scholars and scientists all around the world. Journal of Diabetes & Metabolism has got h-index 44, which means every article in Journal of Diabetes & Metabolism has got 44 average citations.
Following are the list of articles that have cited the articles published in Journal of Diabetes & Metabolism.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|
Total published articles |
123 | 107 | 59 | 61 | 45 | 23 |
Research, Review articles and Editorials |
44 | 54 | 37 | 40 | 21 | 22 |
Research communications, Review communications, Editorial communications, Case reports and Commentary |
5 | 1 | 2 | 5 | 3 | 0 |
Conference proceedings |
6 | 16 | 5 | 7 | 0 | 45 |
Citations received as per Google Scholar, other indexing platforms and portals |
632 | 946 | 1156 | 1199 | 1039 | 1106 |
| Journal total citations count | 11096 |
| Journal impact factor | 12.50 |
| Journal 5 years impact factor | 18.23 |
| Journal cite score | 23.62 |
| Journal h-index | 44 |
| Journal Impact Factor 2020 formula |
| IF= Citations(y)/{Publications(y-1)+ Publications(y-2)} Y= Year |
| Journal 5-year Impact Factor 2020 formula |
| Citations(2016 + 2017 + 2018 + 2019 + 2020)/ {Published articles(2016 + 2017 + 2018 + 2019 + 2020)} |
| Journal citescore |
| Citescorey = Citationsy + Citationsy-1 + Citationsy-2 + Citations y-3 / Published articlesy + Published articlesy-1 + Published articlesy-2 + Published articles y-3 |
Soumya D, Srilatha B. Late stage complications of diabetes and insulin resistance. J Diabetes Metab. 2011 Dec 25;2(9):1000167. |
|
Nishant T, Hima Bindu K, Sathish Kumar D, Arun Kumar R. Pharmacogenomics-Personalized treatment of cancer, diabetes and cardiovascular diseases. J Pharmacogenomics Pharmacoproteomics. 2011;2:107. |
|
Sai YR, Dattatreya A, Anand SY, Suresh Babu D, Sandeep Heni RS. Biomarkers of internal origin and their significance in diabetes and diabetic complications. J Diabetes Metab. 2011;2. |
|
Soumya D, Srilatha B. Late stage complications of diabetes and insulin resistance. J Diabetes Metab. 2011 Dec 25;2(9):1000167. |
|
Liepinsh E, Skapare E, Vavers E, Konrade I, Strele I, Grinberga S, Pugovics O, Dambrova M. High L-carnitine concentrations do not prevent late diabetic complications in type 1 and 2 diabetic patients. Nutrition research. 2012 May 1;32(5):320-7. |
|
Dambrova M, Liepinsh E (2015) Risks and benefits of carnitine supplementation in diabetes. Experimental and Clinical Endocrinology & Diabetes 123: 95-100. |
|
Zabielski P, Lanza IR, Gopala S, Heppelmann CJ, Bergen HR, Dasari S, Nair KS. Altered skeletal muscle mitochondrial proteome as the basis of disruption of mitochondrial function in diabetic mice. Diabetes. 2016 Mar 1;65(3):561-73. |
|
Siddiqui A. Role of diabetes in prevalence of tuberculosis. J Diabetes Metab. 2011 Dec 1;2(170):2. |
|
Stein SA, Lamos EM, Davis SN. A review of the efficacy and safety of oral antidiabetic drugs. Expert opinion on drug safety. 2013 Mar 1;12(2):153-75. |
|
Tran L, Zielinski A, Roach AH, Jende JA, Householder AM, Cole EE, Atway SA, Amornyard M, Accursi ML, Shieh SW, Thompson EE. Pharmacologic treatment of type 2 diabetes: oral medications. Annals of Pharmacotherapy. 2015 May;49(5):540-56. |
|
Soumya D, Srilatha B. Late stage complications of diabetes and insulin resistance. J Diabetes Metab. 2011 Dec 25;2(9):1000167. |
|
Valencia WM, Florez H. Pharmacological treatment of diabetes in older people. Diabetes, Obesity and Metabolism. 2014 Dec;16(12):1192-203. |
|
Lamos EM, Levitt DL, Munir KM. A review of dopamine agonist therapy in type 2 diabetes and effects on cardio-metabolic parameters. Primary Care Diabetes. 2016 Feb 1;10(1):60-5. |
|
Lamos E, Munir KM, Levitt D. Dopamine agonist effects on hyperglycemia and the cardiometabolic profile. |
|
Liang W, Gao L, Li N, Wang B, Wang L, Wang Y, Yang H, You L, Hou J, Chen S, Zhu H. Efficacy and safety of bromocriptine-QR in type 2 diabetes: a systematic review and meta-analysis. Hormone and Metabolic Research. 2015 Oct;47(11):805-12. |
|
Siddiqui A. Role of diabetes in prevalence of tuberculosis. J Diabetes Metab. 2011 Dec 1;2(170):2. |
|
Grunberger G. Novel therapies for the management of type 2 diabetes mellitus: Part 1. Pramlintide and bromocriptineâ€QR (2 型糖尿病治疗新è¯: 第 1 部分. 普兰林肽与溴éšäºâ€QR). Journal of diabetes. 2013 Jun;5(2):110-7. |
|
Yacoub TG. Application of clinical judgment and guidelines to achieving glycemic goals in type 2 diabetes: focus on pharmacologic therapy. Postgraduate medicine. 2014 May 1;126(3):95-106. |
|
Chamarthi B, Ezrokhi M, Rutty D, Cincotta AH. Impact of bromocriptine-QR therapy on cardiovascular outcomes in type 2 diabetes mellitus subjects on metformin. Postgraduate medicine. 2016 Nov 16;128(8):761-9. |
|
Nishant T, Hima Bindu K, Sathish Kumar D, Arun Kumar R. Pharmacogenomics-Personalized treatment of cancer, diabetes and cardiovascular diseases. J Pharmacogenomics Pharmacoproteomics. 2011;2:107. |
|
